📣 VC round data is live. Check it out!
- Public Comps
- Pacific Biosciences
Pacific Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pacific Biosciences and similar public comparables like OmniAb, Myriad Genetics, SOPHiA Genetics, Nautilus Biotechnology and more.
Pacific Biosciences Overview
About Pacific Biosciences
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Founded
2000
HQ

Employees
575
Website
Financials (LTM)
EV
$785M
Valuation Multiples
Start free trialPacific Biosciences Financials
Pacific Biosciences reported last 12-month revenue of $163M and negative EBITDA of ($141M).
In the same LTM period, Pacific Biosciences generated $54M in gross profit, ($141M) in EBITDA losses, and had net loss of ($389M).
Revenue (LTM)
Pacific Biosciences P&L
In the most recent fiscal year, Pacific Biosciences reported revenue of $160M and EBITDA of ($153M).
Pacific Biosciences is unprofitable as of last fiscal year, with gross margin of 29%, EBITDA margin of (95%), and net margin of (341%).
Financial data powered by Morningstar, Inc.
Pacific Biosciences Stock Performance
Pacific Biosciences has current market cap of $357M, and enterprise value of $785M.
Market Cap Evolution
Pacific Biosciences' stock price is $1.15.
Pacific Biosciences share price decreased by 27.7% in the last 30 days, and increased by 19.3% in the last year.
Pacific Biosciences has an EPS (earnings per share) of $-1.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $785M | $357M | 0.0% | -27.7% | -31.5% | 19.3% | $-1.76 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPacific Biosciences Valuation Multiples
Pacific Biosciences trades at 4.8x EV/Revenue multiple, and (5.6x) EV/EBITDA.
EV / Revenue (LTM)
Pacific Biosciences Financial Valuation Multiples
As of May 20, 2026, Pacific Biosciences has market cap of $357M and EV of $785M.
Pacific Biosciences has a P/E ratio of (0.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pacific Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Pacific Biosciences Margins & Growth Rates
Pacific Biosciences grew revenue by 5% but EBITDA decreased by 32% in the last fiscal year.
In the most recent fiscal year, Pacific Biosciences reported gross margin of 29%, EBITDA margin of (95%), and net margin of (341%).
Pacific Biosciences Margins
Pacific Biosciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Pacific Biosciences Operational KPIs
Pacific Biosciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.0M for the same period.
Pacific Biosciences' Rule of 40 is (56%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pacific Biosciences' Rule of X is (49%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Pacific Biosciences Competitors
Pacific Biosciences competitors include OmniAb, Myriad Genetics, SOPHiA Genetics, Nautilus Biotechnology, ToolGen, Fulgent Genetics, Prenetics Global, Abclon, Mirxes Holding and Atrys Health.
Most Pacific Biosciences public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 16.8x | 13.5x | (7.0x) | (7.7x) | |||
| 0.5x | 0.5x | 10.9x | 11.0x | |||
| 4.3x | 4.0x | (8.0x) | (8.7x) | |||
| — | 867.5x | (3.9x) | (3.6x) | |||
| 473.6x | — | (18.2x) | — | |||
| 0.6x | 0.6x | (18.7x) | (6.8x) | |||
| 2.0x | 1.4x | (14.3x) | (12.2x) | |||
| 140.1x | — | (40.4x) | — | |||
This data is available for Pro users. Sign up to see all Pacific Biosciences competitors and their valuation data. Start Free Trial | ||||||
Pacific Biosciences M&A Activity
Pacific Biosciences has acquired 3 companies to date.
Last acquisition by Pacific Biosciences was on August 2nd 2023. Pacific Biosciences acquired Apton Biosystems for $110M (EV/Revenue multiple of ).
Latest Acquisitions by Pacific Biosciences
| Description | Apton Biosystems is a California-based developer of super-resolution optical systems for DNA sequencing and protein detection at sub-wavelength scales. The technology supports biomarker discovery, early disease diagnostics, and therapeutic monitoring, advancing precision medicine applications in research labs worldwide. | Circulomics is a Baltimore-based biotech firm developing kits for long-read sequencing sample preparation and microRNA analysis. Located in IMET's incubator, it has secured $8 million from NIH and TEDCO grants. Products like NanoMotor kits enable single-molecule nucleic acid handling for genomics research and diagnostics. Founded in 2007, Circulomics supplies tools to labs worldwide for biomarker discovery. | — |
| HQ Country | |||
| HQ City | San Francisco, CA | Baltimore, MD | — |
| Deal Date | 2 Aug 2023 | 3 Aug 2021 | 20 Jul 2021 |
| Valuation | $110M | $30M | $800M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Pacific Biosciences acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pacific Biosciences
| When was Pacific Biosciences founded? | Pacific Biosciences was founded in 2000. |
| Where is Pacific Biosciences headquartered? | Pacific Biosciences is headquartered in United States. |
| How many employees does Pacific Biosciences have? | As of today, Pacific Biosciences has over 575 employees. |
| Who is the CEO of Pacific Biosciences? | Pacific Biosciences' CEO is Christian O. Henry. |
| Is Pacific Biosciences publicly listed? | Yes, Pacific Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Pacific Biosciences? | Pacific Biosciences trades under PACB ticker. |
| When did Pacific Biosciences go public? | Pacific Biosciences went public in 2010. |
| Who are competitors of Pacific Biosciences? | Pacific Biosciences main competitors include OmniAb, Myriad Genetics, SOPHiA Genetics, Nautilus Biotechnology, ToolGen, Fulgent Genetics, Prenetics Global, Abclon, Mirxes Holding, Atrys Health. |
| What is the current market cap of Pacific Biosciences? | Pacific Biosciences' current market cap is $357M. |
| What is the current revenue of Pacific Biosciences? | Pacific Biosciences' last 12 months revenue is $163M. |
| What is the current revenue growth of Pacific Biosciences? | Pacific Biosciences revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Pacific Biosciences? | Current revenue multiple of Pacific Biosciences is 4.8x. |
| Is Pacific Biosciences profitable? | No, Pacific Biosciences is not profitable. |
| What is the current EBITDA of Pacific Biosciences? | Pacific Biosciences has negative EBITDA and is not profitable. |
| What is Pacific Biosciences' EBITDA margin? | Pacific Biosciences' last 12 months EBITDA margin is (86%). |
| What is the current EV/EBITDA multiple of Pacific Biosciences? | Current EBITDA multiple of Pacific Biosciences is (5.6x). |
| How many companies Pacific Biosciences has acquired to date? | As of May 2026, Pacific Biosciences has acquired 3 companies. |
| What was the largest acquisition by Pacific Biosciences? | $800M acquisition of Omniome on 20th July 2021 was the largest M&A Pacific Biosciences has done to date. |
| What companies Pacific Biosciences acquired? | Pacific Biosciences acquired Omniome, Apton Biosystems, and Circulomics. |
| In how many companies Pacific Biosciences has invested to date? | Pacific Biosciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Pacific Biosciences
Lists including Pacific Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
